Beam Therapeutics Inc. (BEAM) News
Filter BEAM News Items
BEAM News Results
|Loading, please wait...|
BEAM News Highlights
- BEAM's 30 day story count now stands at 5.
- Over the past 14 days, the trend for BEAM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BASE, ARCH and PEAK are the most mentioned tickers in articles about BEAM.
Latest BEAM News From Around the Web
Below are the latest news stories about Beam Therapeutics Inc that investors may wish to consider to help them evaluate BEAM as an investment opportunity.
In this article, we discuss 10 genomics stocks in Cathie Wood’s portfolio that are underperforming. If you want to skip our detailed analysis of these stocks, go directly to 5 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming. ARK Investment Management is an innovation-focused hedge fund that is headquartered in St. Petersburg, Florida, with […]
In this article, we will discuss the top 10 biotech stocks to buy according to Jeremy Green’s Redmile Group. If you want to skip our detailed analysis of Green’s history, investment philosophy performance, you can go directly to the Top 5 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group. Jeremy Green is the […]
Beam Therapeutics Inc. (NASDAQ:BEAM)’s traded shares stood at 1.13 million during the last session. At the close of trading, the stock’s price was $64.60, to imply a decrease of -5.56% or -$3.8 in intraday trading. The BEAM share’s 52-week high remains $138.52, putting it -114.43% down since that peak but still an impressive 12.79% since … Beam Therapeutics Inc. (NASDAQ: BEAM) Has Fallen -114.43% From Its Highs, What Comes Next? Read More »
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m. ET.
Pfizer (NYSE: PFE) recently announced a collaboration with Beam Therapeutics (NASDAQ: BEAM) to develop gene-editing therapies targeting rare genetic diseases. In this Motley Fool Live video, recorded on Jan. 12., Fool contributors Keith Speights and Brian Orelli discuss why Pfizer's deal with Beam appears to be a smart move. Keith Speights: We mentioned this on Monday I believe, that Pfizer had announced a collaboration with Beam Therapeutics to develop therapies targeting rare genetic diseases.
In this Motley Fool Live video recorded on Jan. 12, 2022, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not the two companies are rising stars in healthcare. Keith Speights: Illumina, which we've talked about, and Beam Therapeutics, she says, "Are they rising stars, and what about other CRISPR stocks?" Are Illumina and Beam rising stars, Brian?
Pfizer (NYSE: PFE) is putting some of its growing cash stockpile to use. The big drugmaker recently announced a collaboration with Acuitas Therapeutics. In this Motley Fool Live video, recorded on Jan. 12, Fool contributors Keith Speights and Brian Orelli discuss why Pfizer is teaming up with Acuitas.
No summary available.
Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo are highlighted in this analyst blog article.
Beam Therapeutics (NASDAQ: BEAM) recently signed a major research deal with Pfizer (NYSE: PFE) that could be worth up to $1.35 billion, and hardly anyone seemed to notice. Instead of surging higher in response to the Pfizer deal, Beam Therapeutics stock actually fell nearly 2% on the day of the announcement. Over the past few years, Pfizer has watched its peers experiment with CRISPR-based gene editing techniques without making any significant investments.